EA028595B1 - Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака - Google Patents

Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака Download PDF

Info

Publication number
EA028595B1
EA028595B1 EA201491399A EA201491399A EA028595B1 EA 028595 B1 EA028595 B1 EA 028595B1 EA 201491399 A EA201491399 A EA 201491399A EA 201491399 A EA201491399 A EA 201491399A EA 028595 B1 EA028595 B1 EA 028595B1
Authority
EA
Eurasian Patent Office
Prior art keywords
molecular weight
low molecular
patient
cancer
weight compound
Prior art date
Application number
EA201491399A
Other languages
English (en)
Russian (ru)
Other versions
EA201491399A1 (ru
Inventor
Игорь Ронинсон
Дональд Си. Портер
Марк Пи. Уэнтланд
Original Assignee
Сенекс Биотекнолоджи Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сенекс Биотекнолоджи Инк. filed Critical Сенекс Биотекнолоджи Инк.
Publication of EA201491399A1 publication Critical patent/EA201491399A1/ru
Publication of EA028595B1 publication Critical patent/EA028595B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
EA201491399A 2012-02-02 2013-02-01 Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака EA028595B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261594023P 2012-02-02 2012-02-02
US61/594,023 2012-02-02
US201261673419P 2012-07-19 2012-07-19
US61/673,419 2012-07-19
PCT/US2013/024515 WO2013116786A1 (en) 2012-02-02 2013-02-01 Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer

Publications (2)

Publication Number Publication Date
EA201491399A1 EA201491399A1 (ru) 2015-04-30
EA028595B1 true EA028595B1 (ru) 2017-12-29

Family

ID=47716178

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201491399A EA028595B1 (ru) 2012-02-02 2013-02-01 Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака
EA201791284A EA032429B1 (ru) 2012-02-02 2013-02-01 Селективные низкомолекулярные ингибиторы cdk8/cdk19 и их применение в качестве агентов для лечения рака

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201791284A EA032429B1 (ru) 2012-02-02 2013-02-01 Селективные низкомолекулярные ингибиторы cdk8/cdk19 и их применение в качестве агентов для лечения рака

Country Status (16)

Country Link
US (2) US9321737B2 (enExample)
EP (2) EP2809324B1 (enExample)
JP (1) JP6193268B2 (enExample)
KR (1) KR20150023223A (enExample)
CN (1) CN104363913B (enExample)
AU (1) AU2013214783B2 (enExample)
BR (1) BR112014019052A8 (enExample)
CL (1) CL2014002062A1 (enExample)
CO (1) CO7151516A2 (enExample)
EA (2) EA028595B1 (enExample)
GE (1) GEP201706688B (enExample)
MY (1) MY165446A (enExample)
PH (1) PH12014501862A1 (enExample)
SG (1) SG11201404596UA (enExample)
UA (1) UA117342C2 (enExample)
WO (1) WO2013116786A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362346B (es) * 2012-07-27 2019-01-11 Biogen Ma Inc Compuestos que son agentes moduladores de s1p y/o agentes moduladores de autotaxina.
MX2015002310A (es) * 2012-08-23 2015-06-05 Hoffmann La Roche Nuevas amidas de fenil-piridina/pirazina para el tratamiento de cancer.
JP6310470B2 (ja) 2012-11-01 2018-04-11 ユニバーシティ オブ サウス カロライナ 前立腺がんを処置するための方法
EP2961409A1 (en) * 2013-02-26 2016-01-06 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
MY180383A (en) 2013-12-24 2020-11-28 Harvard College Cortistatin analogues and syntheses and uses thereof
EP3205645B1 (en) * 2014-04-18 2019-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3154952A4 (en) * 2014-06-10 2018-03-14 University of South Carolina Methods and compositions for treatment of her-positive cancers
US20210322651A1 (en) 2014-12-18 2021-10-21 Senex Biotechnology, Inc. Suppression of neointimal formation following vascular surgeru using cdk8 inhibitors
MX2017014338A (es) * 2015-05-08 2018-04-11 Harvard College Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
KR20180073600A (ko) 2015-11-03 2018-07-02 루 라이센스 에이비 과증식성 장애의 치료를 위한 화합물
WO2017091836A1 (en) * 2015-11-25 2017-06-01 University Of South Carolina Enhancement of cytarabine activity by inhibiting cdk8/19
JP7198489B2 (ja) * 2016-03-23 2023-01-04 国立大学法人 岡山大学 リン酸化ｓａｒｍ１、抗体、ｓａｒｍ１リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、ｓａｒｍ１改変体及び使用
WO2018027082A1 (en) 2016-08-03 2018-02-08 The Broad Institute, Inc. Use of cdk8 inhibitors to treat diseases of inflammation and autoimmunity
CN110234648B (zh) * 2017-01-30 2022-06-14 国立大学法人京都大学 新型化合物以及调节性t细胞的制造方法
WO2018151633A1 (ru) * 2017-02-20 2018-08-23 Закрытое Акционерное Общество "Биокад" Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов
US20220040179A1 (en) * 2017-02-23 2022-02-10 University Of South Carolina Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis
US20190390169A1 (en) * 2017-03-03 2019-12-26 Kyoto University Pancreatic progenitor cell production method
RU2641001C1 (ru) * 2017-04-03 2018-01-15 Закрытое Акционерное Общество "Биокад" Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция
JP7152784B2 (ja) * 2017-04-03 2022-10-13 京都薬品工業株式会社 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
WO2019055977A1 (en) 2017-09-18 2019-03-21 Chan Zuckerberg Biohub, Inc. METHODS OF TREATING NEGATIVE TRIPLE BREAST CANCER
US11261184B2 (en) 2017-10-02 2022-03-01 Boehringer Ingelheim International Gmbh [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
CA3128377A1 (en) 2019-02-01 2020-08-06 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
US20230399607A1 (en) 2020-11-20 2023-12-14 Orizuru Therapeutics, Inc. Maturation agent
US20240318141A1 (en) 2021-02-09 2024-09-26 Orizuru Therapeutics, Inc. Maturation agent
WO2022204534A1 (en) * 2021-03-25 2022-09-29 University Of South Carolina Cdk8/19 inhibitors for the treatment of cytokine storm
TW202330910A (zh) 2021-09-27 2023-08-01 國立大學法人京都大學 Ｔ細胞的製造方法
CA3238860A1 (en) 2021-11-24 2023-06-01 Norihisa MIKAMI Pharmaceutical composition for treating or preventing t cell-related disorders
TW202330911A (zh) 2021-11-24 2023-08-01 日商雷格細胞股份有限公司 人類誘導性控制性ｔ細胞及其製作方法
EP4497822A1 (en) 2022-03-23 2025-01-29 Kyoto University Method for producing regulatory t cells
US20250188420A1 (en) 2022-04-25 2025-06-12 Orizuru Therapeutics, Inc. Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
IL318270A (en) 2022-07-14 2025-03-01 Orizuru Therapeutics Inc Fibrin gel sheet for cell transplantation
EP4600352A1 (en) 2022-09-26 2025-08-13 Kyoto University T cell production method
CN119948155A (zh) 2022-09-26 2025-05-06 雷格细胞股份有限公司 含有嵌合抗原受体（car）的诱导性调节性t细胞
CN120676951A (zh) 2023-02-08 2025-09-19 雷格细胞股份有限公司 用于治疗或预防天疱疮的药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US20040204409A1 (en) * 2003-04-10 2004-10-14 Kazuo Ando Bicyclic compounds as NR2B receptor antagonists
US20080033000A1 (en) * 2006-05-15 2008-02-07 Senex Biotechnology, Inc. Identification of CDKI pathway inhibitors
US20120071477A1 (en) * 2009-11-30 2012-03-22 Senex Biotechnology, Inc. Cdki pathway inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20324A (sl) * 1997-10-27 2001-02-28 Agouron Pharmaceuticals, Inc. Substituirane 4-amino-tiazol-2-il spojine kot cdk inhibitorji
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
US20040180844A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US20040204409A1 (en) * 2003-04-10 2004-10-14 Kazuo Ando Bicyclic compounds as NR2B receptor antagonists
US20080033000A1 (en) * 2006-05-15 2008-02-07 Senex Biotechnology, Inc. Identification of CDKI pathway inhibitors
US20120071477A1 (en) * 2009-11-30 2012-03-22 Senex Biotechnology, Inc. Cdki pathway inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. C. PORTER, E. FARMAKI, S. ALTILIA, G. P. SCHOOLS, D. K. WEST, M. CHEN, B.-D. CHANG, A. T. PUZYREV, C.-U. LIM, R. ROKOW-KITTELL,: "Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 34, 21 August 2012 (2012-08-21), pages 13799 - 13804, XP055056523, ISSN: 00278424, DOI: 10.1073/pnas.1206906109 *
VICTOR���J. CEE, DAVID���Y.-K. CHEN, MATTHEW���R. LEE, K.�&#: "Cortistatin���A is a High-Affinity Ligand of Protein Kinases ROCK, CDK8, and CDK11", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, ¬VERLAG CHEMIE| :, vol. 48, no. 47, 9 November 2009 (2009-11-09), pages 8952 - 8957, XP055056483, ISSN: 14337851, DOI: 10.1002/anie.200904778 *

Also Published As

Publication number Publication date
CN104363913B (zh) 2018-08-21
JP6193268B2 (ja) 2017-09-06
WO2013116786A1 (en) 2013-08-08
EA201491399A1 (ru) 2015-04-30
BR112014019052A8 (pt) 2017-07-11
EP3431087A1 (en) 2019-01-23
BR112014019052A2 (enExample) 2017-06-20
SG11201404596UA (en) 2014-10-30
EP2809324B1 (en) 2018-08-01
EA201791284A1 (ru) 2017-10-31
EP2809324A1 (en) 2014-12-10
PH12014501862A1 (en) 2014-11-24
UA117342C2 (uk) 2018-07-25
CO7151516A2 (es) 2014-12-29
AU2013214783B2 (en) 2017-07-06
US20170071942A1 (en) 2017-03-16
MY165446A (en) 2018-03-22
GEP201706688B (en) 2017-06-26
US10993945B2 (en) 2021-05-04
US20140038958A1 (en) 2014-02-06
CL2014002062A1 (es) 2015-03-20
JP2015506376A (ja) 2015-03-02
KR20150023223A (ko) 2015-03-05
CN104363913A (zh) 2015-02-18
AU2013214783A1 (en) 2014-08-28
US9321737B2 (en) 2016-04-26
EA032429B1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
EA028595B1 (ru) Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака
US11452725B2 (en) Chiral diaryl macrocycles and uses thereof
ES2915833T3 (es) Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular
ES3043134T3 (en) Therapeutic conjugates
EP3917934A2 (en) Compounds and uses thereof
KR20070115879A (ko) 의학 장애의 치료용 ｃｘｃｒ4 길항제
CN109111408B (zh) 噻唑啉酮杂环化合物、其制备方法、药用组合物及应用
KR20170001962A (ko) 항 악성 종양제 조성물
CN112638889A (zh) 用于治疗的尿石素a和其衍生物
US12428405B2 (en) Chalcone-based chemotherapeutic compound for triple negative breast cancer
US20240150348A1 (en) Brd9 degraders and uses thereof
US11420977B2 (en) Late SV40 (LSF) inhibitors
US20230293539A1 (en) Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
US11427543B2 (en) Compounds for targeting cancer stem cells
JP6782710B2 (ja) Ｒａｃ−ＧＴＰアーゼ媒介性障害を処置するための化合物
US11351144B2 (en) Compounds for inhibiting secretory leukocyte protease inhibitor (SLPI)
US20250122193A1 (en) Novel pyridocarbazolium compounds and medical uses thereof
US20250368629A1 (en) Flavonoid compounds and methods and materials for using flavonoid compounds to treat fibrotic conditions
US20220193056A1 (en) Compositions and methods of treating pik3ca helical domain mutant cancers
CN121221768A (zh) 靶向ccr1的抑制剂在制备治疗肺癌骨转移癌药物中的应用
WO2025255213A1 (en) Niclosamide prodrugs for treating cancers
KR20250138853A (ko) Il-6 저해제 및 이를 포함하는 il-6 매개된 질병의 치료용 약학 조성물
WO2021157613A1 (ja) ピラゾール誘導体及び医薬組成物
HK40074912B (zh) 用ezh2抑制剂治疗mrto/sccoht的方法
JP2023530734A (ja) アイソフォーム特異的アルデヒドデヒドロゲナーゼ阻害剤

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU